Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Phase 2
Terminated
NCT05785715
| Condition | Ulcerative Colitis |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | AbbVie |
|---|
| Status | Terminated |
|---|
| Enrollment | 81 participants |
|---|
| Interventions | NX-13 250mg, NX-13 750mg, NX-13 Placebo |
|---|
| Start date | Apr 24, 2023 |
|---|
| Completion date | May 30, 2025 |
|---|
| Results posted | Jun 15, 2026 |
|---|
Summary
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
Change From Baseline in Modified Mayo Score (MMS) at Week 12
Baseline, Week 12 · score on a scale
| Induction Period: NX-13 250 mg | -2.29 ± 0.41 score on a scale |
|---|
| Induction Period: NX-13 750 mg | -1.98 ± 0.40 score on a scale |
|---|
| Induction Period: Placebo | -2.11 ± 0.59 score on a scale |
|---|
| LS Mean Difference | -0.18 (95% CI -1.33–0.97) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.